Burns Market Set to Experience Unprecedented Growth During the Forecast Period (2023-32) – Asserts DelveInsight | MediWound, Kaken Pharma, Kerecis, Mallinckrodt, Avita Medical, KeraNetics, PolyNovo

Burns Market Set to Experience Unprecedented Growth During the Forecast Period (2023-32) -  Asserts DelveInsight | MediWound, Kaken Pharma, Kerecis, Mallinckrodt, Avita Medical, KeraNetics, PolyNovo
Delveinsight Business Research LLP
The Burns Market is set to show an extensive jump by the end of 2032 and is anticipated to grow at a CAGR of 1.99% during the study period (2019–2032) in the 7MM. The Burns Market is expected to show positive growth in the upcoming years, mainly attributed to the increase in population, rising incidence of burn injury, and the expected launch of upcoming therapies.

DelveInsight’s “Burns Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Burns market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Burns drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Burns treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Burns: An Overview

Burn injuries are underappreciated injuries that are associated with substantial morbidity and mortality. Burn injuries, particularly severe burns, are accompanied by an immune and inflammatory response, metabolic changes, and distributive shock that can be challenging to manage and can lead to multiple organ failures. Of great importance is that the injury affects not only physical health but also the patient’s mental health and quality of life.

Burn injuries are underappreciated trauma that can affect anyone, anytime and anywhere. The injuries can be caused by friction, cold, heat, radiation, chemical, or electric sources, but most burn injuries are caused by heat from hot liquids, solids, or fire. Although all burn injuries involve tissue destruction due to energy transfer, different causes can be associated with different physiological and pathophysiological responses.

In addition to determining the cause of a burn injury, it is imperative to classify the injury according to its severity –its depth and size. Burns that affect the uppermost layer of the skin (epidermis only) are classed as superficial (first-degree) burns; the skin becomes red, and the pain experienced is limited in duration. Superficial partial-thickness (second-degree) burns (formerly known as 2A burns) are painful, weep, require dressing and wound care, and may scar but do not require surgery. Deep partial-thickness (second-degree) burns (formerly known as 2B burns) are less painful due to the partial destruction of the pain receptors, which are drier, require surgery, and will scar. A full-thickness (third-degree) burn extends through the full dermis and is not typically painful owing to damage to the nerve endings and requires protection from becoming infected and, unless minimal, surgical management.

Burns Market Key Facts

  • The market size for Burns injury was USD 827 million in 2021 in the United States.

  • The Burns market size in the EU5 was USD 491 million in 2021. EU5 accounted for nearly 32% of the total 7MM market size. 

  • Among the EU5 countries, the United Kingdom holds the highest market size of USD 160 million, followed by France (USD 103 million) and Germany (USD 85 million). Spain holds the least market size of USD 71 million among the EU5 countries in 2021.

  • The Burns market size in Japan was USD 222 million in 2021. Japan accounted for 14% of the total 7MM market size.

  • In 2021, the total incident population of burn injuries that required medical treatment in seven major markets was reported to be 1,864,208.

  • The estimates suggest the United States had the highest incident population of burn injuries that required medical treatment, with 661,900 cases in 2021.

  • According to our analysis, after fire/flame (41%), scald was the foremost contributing cause of burn injuries in the US, occupying 31.4% of total incident cases of treatment-taking burn injuries.

  • According to our assessments for the United States, the estimated cases of hospitalized burn patients in 2021 were 76,383.

  • Japan had 328,255 incident cases of burn injuries requiring medical treatment in 2021, the second-highest of all other countries in 7MM after the US.

Burns Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Burns pipeline therapies. It also thoroughly assesses the Burns market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Burns drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Burns Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Burns epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Burns epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Burns Epidemiology, Segmented as –

  • Incident Cases of Burn Patients Requiring Treatment

  • Gender-specific Incident Cases of Treated Burn Injuries

  • Etiology-specific Incident Cases of Treated Burn Injuries

  • Severity-specific Incident Cases of Treated Burn Injuries

  • Incident Cases of Hospitalized Burn Patients Scenario

Burns Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Burns market or expected to be launched during the study period. The analysis covers the Burns market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Burns drugs based on their sale and market share.

The report also covers the Burns pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Burns companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Burns Market Will Evolve and Grow by 2032 @ 


Burns Therapeutics Analysis

In the current market scenario, the standard treatment for skin burns involves medications, wound dressings, therapy, and surgery. The treatment goals are to control pain, remove dead tissue, prevent infection, reduce scarring risk, and regain function. The treatment depends on the severity of the burn.

Medical treatment includes water-based treatments (Ultrasound mist therapy to clean and stimulate the wound tissue), fluids to prevent dehydration (intravenous (IV) fluids to prevent dehydration and organ failure), pain and anxiety medications (morphine and anti-anxiety medications), creams and ointments (bacitracin and silver sulfadiazine), dressings (wound dressings), and common topical antimicrobials such as silver sulfadiazine (SSD), cerium plus SSD, silver nitrate, mafenide, bacitracin, and Xeroform.

Additionally, because children have limited glycogen stores, they should be given weight-based maintenance intravenous fluid in the form of 5% dextrose in 4.5% normal saline in addition to burning resuscitation fluid. Elderly patients have a unique acute phase response after burn injury, characterized by decreased organ perfusion and oxygenation.

To further improve the treatment outlook, several major pharma and biotech companies are developing therapies for Burns. Currently, NeoMatrix Therapeutics is leading the therapeutics market with its Burns drug candidates in the most advanced stage of clinical development.

Burns Companies Actively Working in the Therapeutics Market Include

MediWound Germany GmbH, Kaken Pharmaceutical Co., Ltd., Kerecis, Mallinckrodt Pharmaceuticals, Avita Medical, Vericel Corporation, KeraNetics, Integra LifeSciences Corporation, PolyNovo, Medline Industries, Anika Therapeutics, Inc., ACell, Inc., Amryt Pharma, CUTISS AG, Skingenix, RenovaCare, and others.

Emerging and Marketed Burns Therapies Covered in the Report Include:

  • NexoBrid/KMW-1: MediWound Germany GmbH/Kaken Pharmaceutical Co., Ltd.

  • Kerecis Omega3: Kerecis

  • StrataGraft: Mallinckrodt Pharmaceuticals

  • MW-III: Skingenix

  • EHSG-KF (denovoSkin): CUTISS AG

And Many Others

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @


Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Burns Competitive Intelligence Analysis

4. Burns Market Overview at a Glance

5. Burns Disease Background and Overview

6. Burns Patient Journey

7. Burns Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Burns Treatment Algorithm, Current Treatment, and Medical Practices

9. Burns Unmet Needs

10. Key Endpoints of Burns Treatment

11. Burns Marketed Therapies

12. Burns Emerging Drugs and Latest Therapeutic Advances

13. Burns Seven Major Market Analysis

14. Attribute Analysis

15. Burns Market Outlook (In US, EU5, and Japan)

16. Burns Companies Active in the Market

17. Burns Access and Reimbursement Overview

18. KOL Views on the Burns Market

19. Burns Market Drivers

20. Burns Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @




About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Campylobacter Infections Market

“Campylobacter Infections Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Campylobacter Infections market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Campylobacter Infections market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices